Protalix BioTherapeutics, Inc.
PLX
$1.93
$0.021.05%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -325.24% | 156.15% | 142.70% | -42.93% | -64.73% |
| Total Depreciation and Amortization | 12.35% | 10.05% | 8.74% | 7.70% | 9.49% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -10.53% | -44.92% | 35.66% | 610.82% | 760.66% |
| Change in Net Operating Assets | -1,345.25% | -260.59% | -281.48% | -419.85% | 107.70% |
| Cash from Operations | -238.26% | -221.19% | 19.15% | -109.75% | 758.12% |
| Capital Expenditure | -27.77% | -49.95% | 14.86% | 33.96% | -11.58% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -113.24% | -173.46% | 126.79% | 126.77% | 135.34% |
| Cash from Investing | -156.05% | -186.33% | 119.34% | 120.48% | 125.26% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -- | -- | -- |
| Issuance of Common Stock | 157.20% | -- | -- | -16.59% | -85.30% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 155.53% | 162.71% | -- | -212.32% | -168.09% |
| Foreign Exchange rate Adjustments | -288.00% | 167.86% | 176.19% | 130.38% | 121.93% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -31.13% | -296.57% | 77.79% | -33.02% | -159.39% |